Net Income for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $4.50B USD. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingNet IncomeSwitch metric
TTM (last 4 quarters)
$4.50B
YoY change
+2.1%
5Y CAGR
+5.1%
Peak year (2021)
$8.08B
Cumulative net income
$36.34B
Net Income history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Net Income history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Net Income | YoY |
|---|---|---|---|---|
| 2025 | $4.50B | +2.1% | ||
| 2024 | $4.41B | +11.6% | ||
| 2023 | $3.95B | -8.9% | ||
| 2022 | $4.34B | -46.3% | ||
| 2021 | $8.08B | +129.9% | ||
| 2020 | $3.51B | +66.0% | ||
| 2019 | $2.12B | -13.4% | ||
| 2018 | $2.44B | +104.0% | ||
| 2017 | $1.20B | +33.8% | ||
| 2016 | $895.52M | +40.8% | ||
| 2015 | $636.06M | +82.7% | ||
| 2014 | $348.07M | -18.0% | ||
| 2013 | $424.36M | -43.4% | ||
| 2012 | $750.27M | -438.3% | ||
| 2011 | -$221.76M | +112.3% | ||
| 2010 | -$104.47M | +54.0% | ||
| 2009 | -$67.83M | -18.0% | ||
| 2008 | -$82.71M | -21.7% | ||
| 2007 | -$105.60M | +3.2% | ||
| 2006 | -$102.34M | +7.2% | ||
| 2005 | -$95.45M | -328.9% | ||
| 2004 | $41.70M | -138.8% | ||
| 2003 | -$107.46M | -13.6% | ||
| 2002 | -$124.38M | +63.3% | ||
| 2001 | -$76.18M | +228.1% | ||
| 2000 | -$23.21M | +0.5% | ||
| 1999 | -$23.10M | +168.6% | ||
| 1998 | -$8.60M | -25.9% | ||
| 1997 | -$11.60M | -64.2% | ||
| 1996 | -$32.40M | +37.9% | ||
| 1995 | -$23.50M | -23.5% | ||
| 1994 | -$30.70M | -23.1% | ||
| 1993 | -$39.90M | +108.9% | ||
| 1992 | -$19.10M | +324.4% | ||
| 1991 | -$4.50M | +36.4% | ||
| 1990 | -$3.30M | — |
Net Income values are taken from Regeneron Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Regeneron Pharmaceuticals (REGN) net income totalled $4.50B – edged up 2.1% year-over-year.
Regeneron Pharmaceuticals net income compound annual growth for the 2020–2025 (5 years) window is +5.1%, sustaining 2 straight years of year-over-year growth.
Regeneron Pharmaceuticals net income peaked at $8.08B in 2021; the latest annual figure is $4.50B in 2025 (44.2% below peak).
The dataset's maximum net income sits at $8.08B (2021); the minimum reading of -$221.76M dates to 2011.
Regeneron Pharmaceuticals (REGN) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $15.15B.
Regeneron Pharmaceuticals Net Income by Year
Regeneron Pharmaceuticals Net Income 2025: $4.50B
Regeneron Pharmaceuticals net income in 2025 was $4.50B, edged up 2.1% from 2024.
Regeneron Pharmaceuticals Net Income 2024: $4.41B
Regeneron Pharmaceuticals net income in 2024 was $4.41B, grew 11.6% from 2023.
Regeneron Pharmaceuticals Net Income 2023: $3.95B
Regeneron Pharmaceuticals net income in 2023 was $3.95B, declined 8.9% below 2022.
Regeneron Pharmaceuticals Net Income 2022: $4.34B
Regeneron Pharmaceuticals net income in 2022 was $4.34B, plunged 46.3% below 2021.
Regeneron Pharmaceuticals Net Income 2021: $8.08B
Regeneron Pharmaceuticals net income in 2021 was $8.08B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Net Income
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest net income.
| Company | Net Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $102.43B | Healthcare |
| Johnson & Johnson (JNJ) | $26.80B | Healthcare |
| Eli Lilly and Company (LLY) | $20.64B | Healthcare |
| Merck & Co., Inc. (MRK) | $18.25B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $12.06B | Healthcare |
| AstraZeneca PLC (AZN) | $10.26B | Healthcare |
| Amgen Inc. (AMGN) | $7.71B | Healthcare |
| AbbVie Inc. (ABBV) | $4.23B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's net income?
- Latest reported net income for Regeneron Pharmaceuticals (REGN) is $4.50B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals net income changed year-over-year?
- Regeneron Pharmaceuticals (REGN) net income changed +2.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals net income?
- Regeneron Pharmaceuticals (REGN) net income compound annual growth rate is +5.1% over the most recent 5 years available.
When did Regeneron Pharmaceuticals net income hit its highest annual value?
- Regeneron Pharmaceuticals net income reached its highest annual value of $8.08B in 2021.
What was Regeneron Pharmaceuticals net income in 2024?
- Regeneron Pharmaceuticals (REGN) net income in 2024 was $4.41B.
What was Regeneron Pharmaceuticals net income in 2025?
- Regeneron Pharmaceuticals (REGN) net income in 2025 was $4.50B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.